After years of business and lawsuit-fueled decline, is a Teva turnaround in sight?

After years of business and lawsuit-fueled decline, is a Teva turnaround in sight?

Source: 
Endpoints
snippet: 

For five years, Teva’s stock tumbled amid a potent cocktail of serious and widespread legal allegations, declining company and industry-wide revenue and debt that creaked more heavily each passing year. Now, their CEO and some investors think they can see the light.